← back to search

Stefano Pileri

Istituto Oncologico Veneto · IT
🔎 Find collaborators in Pathology and Forensic Medicine · Genetics →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, and Cutaneous lymphoproliferative disorders research.
h-index
114
citations
57,616
works
1,016
NIH funding
primary concept
Medicine
email

Recent publications

Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels.
2025cited by 11position: contributordoi
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma
American Journal of Hematology 2025cited by 6position: middledoi
Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Clinical Cancer Research 2025cited by 4position: middledoi
Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.
2025cited by 1position: contributordoi
Supplementary Figure S6 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S3 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S4 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S5 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Data from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Table S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Table S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Table S3 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S7 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Table S4 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
CD5 deletion enhances the antitumor activity of adoptive T cell therapies.
2024cited by 38position: contributordoi
Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases.
2024cited by 0position: contributordoi
Correction to: Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
2024cited by 0position: contributordoi
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
Nature Communications 2023cited by 32position: middledoi
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
2023cited by 8position: contributordoi
Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
2023cited by 8position: contributordoi
A Microenvironment-Related Nine-Gene Signature May Predict Survival in Mycosis Fungoides Patients at Diagnosis.
2023cited by 3position: contributordoi
Mediastinal Gray-Zone Lymphoma: Still an Open Issue
Hemato 2023cited by 2position: contributordoi
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
2023cited by 1position: contributordoi
Gray-Zone Lymphoma: A Still Open Issue
2023cited by 0position: contributordoi
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood 2022cited by 1,450position: middledoi
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
2022cited by 1,084position: contributordoi
Genomic profiling for clinical decision making in lymphoid neoplasms
Blood 2022cited by 158position: middledoi
Genomic profiling for clinical decision making in lymphoid neoplasms.
2022cited by 123position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 23 papers (2019–2025)Elena Sabattini · Azienda USL di Bologna10 papers (2017–2024)Claudio Agostinelli · Hospital for Sick Children7 papers (2013–2025)Federica Melle · Istituti di Ricovero e Cura a Carattere Scientifico7 papers (2021–2024)Julie M. Vose · University of Nebraska at Omaha6 papers (2018–2023) · 6 papers (2021–2024)Giorgio Inghirami · Cornell University6 papers (2012–2021) · 5 papers (2013–2025)Ranjana H. Advani · Stanford Medicine5 papers (2016–2023)Francesco Bertoni · Sapienza University of Rome5 papers (2012–2020)Maria Rosaria Sapienza · Northern Marianas College5 papers (2019–2023) · 4 papers (2013–2025)Pier Luigi Zinzani · Marche Polytechnic University4 papers (2015–2023) · 4 papers (2019–2023)Fabio Fuligni · Hospital for Sick Children4 papers (2013–2019) · 3 papers (2013–2019) · 3 papers (2013–2025)Thomas Tousseyn · Catholic University of America3 papers (2013–2024)Elaine S. Jaffe · National Institutes of Health3 papers (2016–2022)Giovanna Motta · Azienda USL di Bologna3 papers (2020–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pathology and Forensic Medicine · Genetics →